Artificial intelligence in the diagnosis of prostate cancer

2021 ◽  
Vol 83 (3) ◽  
pp. 38
Author(s):  
G.V. Popov ◽  
A.A. Chub ◽  
Yu.V. Lerner ◽  
L.V. Tsoy ◽  
A.V. Dubinina ◽  
...  
2021 ◽  
Author(s):  
Ying Hou ◽  
Yi-Hong Zhang ◽  
Jie Bao ◽  
Mei-Ling Bao ◽  
Guang Yang ◽  
...  

Abstract Purpose: A balance between preserving urinary continence and achievement of negative margins is of clinical relevance while implementary difficulty. Preoperatively accurate detection of prostate cancer (PCa) extracapsular extension (ECE) is thus crucial for determining appropriate treatment options. We aimed to develop and clinically validate an artificial intelligence (AI)-assisted tool for the detection of ECE in patients with PCa using multiparametric MRI. Methods: 849 patients with localized PCa underwent multiparametric MRI before radical prostatectomy were retrospectively included from two medical centers. The AI tool was built on a ResNeXt network embedded with a spatial attention map of experts’ prior knowledges (PAGNet) from 596 training data sets. The tool was validated in 150 internal and 103 external data sets, respectively; and its clinical applicability was compared with expert-based interpretation and AI-expert interaction.Results: An index PAGNet model using a single-slice image yielded the highest areas under the receiver operating characteristic curve (AUC) of 0.857 (95% confidence interval [CI], 0.827-0.884), 0.807 (95% CI, 0.735-0.867) and 0.728 (95% CI, 0.631-0.811) in the training, internal test and external test cohorts, compared to the conventional ResNeXt networks. For experts, the inter-reader agreement was observed in only 437/849 (51.5%) patients with a Kappa value 0.343. And the performance of two experts (AUC, 0.632 to 0.741 vs 0.715 to 0.857) was lower (paired comparison, all p values < 0.05) than that of AI assessment. When expert’ interpretations were adjusted by the AI assessments, the performance of both two experts was improved.Conclusion: Our AI tool, showing improved accuracy, offers a promising alternative to human experts for imaging staging of PCa ECE using multiparametric MRI.


2021 ◽  
Vol Volume 13 ◽  
pp. 31-39 ◽  
Author(s):  
Derek J Van Booven ◽  
Manish Kuchakulla ◽  
Raghav Pai ◽  
Fabio S Frech ◽  
Reshna Ramasahayam ◽  
...  

2021 ◽  
pp. jclinpath-2020-207351
Author(s):  
Jenny Fitzgerald ◽  
Debra Higgins ◽  
Claudia Mazo Vargas ◽  
William Watson ◽  
Catherine Mooney ◽  
...  

Clinical workflows in oncology depend on predictive and prognostic biomarkers. However, the growing number of complex biomarkers contributes to costly and delayed decision-making in routine oncology care and treatment. As cancer is expected to rank as the leading cause of death and the single most important barrier to increasing life expectancy in the 21st century, there is a major emphasis on precision medicine, particularly individualisation of treatment through better prediction of patient outcome. Over the past few years, both surgical and pathology specialties have suffered cutbacks and a low uptake of pathology specialists means a solution is required to enable high-throughput screening and personalised treatment in this area to alleviate bottlenecks. Digital imaging in pathology has undergone an exponential period of growth. Deep-learning (DL) platforms for hematoxylin and eosin (H&E) image analysis, with preliminary artificial intelligence (AI)-based grading capabilities of specimens, can evaluate image characteristics which may not be visually apparent to a pathologist and offer new possibilities for better modelling of disease appearance and possibly improve the prediction of disease stage and patient outcome. Although digital pathology and AI are still emerging areas, they are the critical components for advancing personalised medicine. Integration of transcriptomic analysis, clinical information and AI-based image analysis is yet an uncultivated field by which healthcare professionals can make improved treatment decisions in cancer. This short review describes the potential application of integrative AI in offering better detection, quantification, classification, prognosis and prediction of breast and prostate cancer and also highlights the utilisation of machine learning systems in biomarker evaluation.


2020 ◽  
Vol 189 ◽  
pp. 105316 ◽  
Author(s):  
Rogier R. Wildeboer ◽  
Ruud J.G. van Sloun ◽  
Hessel Wijkstra ◽  
Massimo Mischi

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17507-e17507
Author(s):  
Vipal P. Durkal ◽  
Nicholas George Nickols ◽  
Matthew Rettig

e17507 Background: Prostate cancer commonly metastasizes to the bone and is associated with reduced survival, pathologic fractures and bone pain. The assessment of bone lesions is made with the technetium Tc99m(99mTc) bone scan, which relies on the subjective interpretation of radiologists and has a wide interobserver variability. There is an unmet need for a more objective and quantifiable measurement tool. Progenics Pharmaceuticals has introduced an automated bone scan index (aBSI), which employs artificial intelligence to quantify skeletal tumor burden. The automated bone scan index has been prospectively validated and is reproducible in large Phase III studies. The aBSI was validated by our study in the Veteran population at the West LA VA Medical Center. Methods: The first positive technetium 99 Tc99m bone scans of veterans diagnosed with metastatic, castration-sensitive prostate cancer were evaluated. Since 2011, a total of 107 evaluable patient bone scans were studied (n = 107). Patients with visceral metastases were excluded to evaluate only those with skeletal metastases. An automated bone scan index (aBSI) was generated for each scan using the Progenics Pharmaceuticals’ artificial intelligence platform. Multivariate analysis of aBSI with overall survival, prostate cancer specific survival, time from diagnosis to first positive bone scan, age at diagnosis, ethnicity, and Gleason score was assessed. Results: The study demonstrated a wide range of aBSI values (Range 0-16.84). Values calculated above the Median aBSI value (1.0) were prognostic for Overall Survival (p = 0.0009) and Prostate Cancer-Specific Survival (p = 0.0011). Patients in the highest quartile of aBSI values (range 5.2-16.84) showed a statistically significant Prostate Cancer-Specific Mortality (p = 0.0300) when compared to the lowest two quartiles (Range 0-1.07). The time from diagnosis to the first positive Tc99m bone scan statistically correlated with aBSI values (p = 0.0016). Multivariate analysis using Cox regression was utilized in the final statistical analysis of prostate cancer-specific mortality and overall survival. Conclusions: The automated Bone Scan Index provides a quantifiable and validated artificial intelligence biomarker to address an unmet need among metastatic prostate cancer patients. This tool was validated among Veterans, a pertinent population that is commonly affected by metastatic prostate cancer.


2018 ◽  
Vol 17 (2) ◽  
pp. e888-e889 ◽  
Author(s):  
Y. Oishi ◽  
T. Kitta ◽  
N. Shinohara ◽  
H. Nosato ◽  
H. Sakanashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document